CTRI/2023/03/050698已完成3 期
A phase III clinical trial to assess the efficacy and safety of Dydrogesterone Extended Release Tablets 20mg as compared to Dydrogesterone Tablets 10mg for treatment of endometriosis in women.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Female patients of age 18-45 years (both inclusive).
- •2. Patients diagnosed with endometriosis based on USG
- •3. Patients with endometriosis associated pain score of at least 30mm on
- •100mm visual analog scale
- •4. Patients willing to give written informed consent and comply with the study
排除标准
- •1. Pregnant or Lactating females; or female patients of childbearing potential unwilling to use effective contraception
- •2. Patients who have achieved menopause or have premature ovarian insufficiency
- •3. Patients undergoing treatment for infertility by assisted reproductive technologies or any other procedure.
- •4. Patients with laparoscopic surgery for endometriosis within last 6 months
- •5. Patients who have taken hormone therapy (danazol, progestins or other sex hormones, corticosteroids, GnRH analogs or gestrinone) in last 6 months or oral contraceptives in last 3 months
- •6. Patients regularly using analgesics not intended to relieve endometriosis related chronic pelvic pain (e.g. using analgesics for osteoarthritis etc)
- •7. Patients with any other significant concomitant gynecological disorder (fibroid etc)
- •8. Subjects with active or recent (within 6 months) arterial thromboembolic disease (e.g. angina, myocardial infarction) or venous thromboembolism (deep vein thrombosis, pulmonary embolism) or at high risk of venous or arterial thrombosis.
- •9. Subjects with hepatic dysfunction (serum transaminases = 3 x Upper Normal Limit) or renal dysfunction (serum creatinine = 2.5 mg/dl)
- •10. Subjects with any other clinically significant uncontrolled systemic diseases such as gastrointestinal, respiratory, cardiovascular, renal, neurological, psychiatric, endocrine (diabetes), immunological or hematological disorders or malignancy
- •11. Subjects with continuing history of alcohol and/or drug abuse
- •12. Subjects with history of allergy to Dydrogesterone or other similar hormonal products
- •13. Participation in another clinical trial in the past 3 months prior to screening
- •14. Any other reason for which the investigator feels that patient should not participate
研究者
相似试验
进行中（未招募）
不适用
Confirmatory study to evaluate the efficacy and safety of chondroitin sulphate and glucosamine sulphate in combination in the treatment of patients with osteoarthritis of the knee compared to placebo.EUCTR2013-000444-26-ESTedec-Meiji Farma, S.A.
进行中（未招募）
1 期
Efficacy and safety of delgocitinib cream in adolescents 12-17 years of age with moderate to severe chronic hand eczemaEUCTR2021-006340-27-BEEO Pharma A/S92
进行中（未招募）
1 期
Efficacy and safety of delgocitinib cream in adolescents 12-17 years of age with moderate to severe chronic hand eczemaEUCTR2021-006340-27-FREO Pharma A/S92
进行中（未招募）
1 期
Efficacy and safety of delgocitinib cream in adolescents 12-17 years of age with moderate to severe chronic hand eczemaEUCTR2021-006340-27-ESEO Pharma A/S92
进行中（未招募）
1 期
Efficacy and safety of delgocitinib cream in adolescents 12-17 years of age with moderate to severe chronic hand eczemaEUCTR2021-006340-27-PLEO Pharma A/S92